Patents by Inventor Brenton Scott

Brenton Scott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240033348
    Abstract: Certain embodiments are directed to compositions and methods for attenuating allergic responses in a subject.
    Type: Application
    Filed: October 11, 2023
    Publication date: February 1, 2024
    Inventors: Burton F. DICKEY, Michael J. TUVIM, Scott E. EVANS, Magnus HOOK, David P. HUSTON, Margarita MARTINEZ-MOCZYGEMBA, Brenton SCOTT
  • Patent number: 11826422
    Abstract: Embodiments are directed to methods and compositions for modulating an immune response. In certain aspects the immune response is a type I hypersensitivity response. In particular aspects the subject has allergic asthma or allergic rhinitis. Using a conventional experimental asthma mouse model (BALB/c), the inventors demonstrate that aerosol administration of TLR agonists, in particular a combination of TLR2/6 and TLR9 agonist (e.g., TLR9 oligonucleotide agonist/PAM2CSK4) along with an antigen (e.g., ovalbumin (OVA)) suppresses the immune response as exemplified by the production of antigen-specific IgE and decreases the number of airway eosinophils in bronchoalveolar lavage fluid (BAL) in response to intraperitoneal (IP) immunization with an antigen mixed with alum.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: November 28, 2023
    Assignee: Board of Regents, the University of Texas System
    Inventors: Burton F. Dickey, Michael J. Tuvim, Scott E. Evans, Magnus Hook, David P. Huston, Margarita Martinez-Moczygemba, Brenton Scott
  • Publication number: 20190314497
    Abstract: Embodiments are directed to compositions and methods for treating viral infections.
    Type: Application
    Filed: April 25, 2019
    Publication date: October 17, 2019
    Inventors: Burton DICKEY, Scott EVANS, Brian Gilbert, Diane Markesich, Brenton Scott, Michael TUVIM
  • Publication number: 20190269773
    Abstract: Embodiments are directed to methods and compositions for modulating an immune response. In certain aspects the immune response is a type I hypersensitivity response. In particular aspects the subject has allergic asthma or allergic rhinitis. Using a conventional experimental asthma mouse model (BALB/c), the inventors demonstrate that aerosol administration of TLR agonists, in particular a combination of TLR2/6 and TLR9 agonist (e.g., TLR9 oligonucleotide agonist/PAM2CSK4) along with an antigen (e.g., ovalbumin (OVA)) suppresses the immune response as exemplified by the production of antigen-specific IgE and decreases the number of airway eosinophils in bronchoalveolar lavage fluid (BAL) in response to intraperitoneal (IP) immunization with an antigen mixed with alum.
    Type: Application
    Filed: November 9, 2017
    Publication date: September 5, 2019
    Inventors: Burton F. DICKEY, Michael J. TUVIM, Scott E. Evans, Magnus HOOK, David P. HUSTON, Margarita MARTINEZ-MOCZYGEMBA, Brenton SCOTT
  • Patent number: 10286065
    Abstract: Embodiments are directed to compositions and methods for treating viral infections.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: May 14, 2019
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, BAYLOR COLLEGE OF MEDICINE, PULMOTECT, INC.
    Inventors: Burton Dickey, Scott Evans, Brian Gilbert, Diane Markesich, Brenton Scott, Michael Tuvim
  • Publication number: 20160082103
    Abstract: Embodiments are directed to compositions and methods for treating viral infections.
    Type: Application
    Filed: September 21, 2015
    Publication date: March 24, 2016
    Inventors: Burton DICKEY, Scott EVANS, Brian Gilbert, Diane Markesich, Brenton Scott, Michael TUVIM
  • Patent number: D1022432
    Type: Grant
    Filed: October 7, 2022
    Date of Patent: April 16, 2024
    Assignee: Wolverine Outdoors, Inc.
    Inventor: Brenton Scott Wehrmeyer